Overview
Dilraj Grewal, MD is a tenured Associate Professor of Ophthalmology at the Duke Eye Center. He specializes in the medical and surgical management of patients with complex Vitreoretinal pathology and Uveitis. He joined the Duke Eye Center following completion of his Vitreoretinal Surgery fellowship at Duke and Uveitis fellowship training at Moorfields Eye Hospital in London. Dr. Grewal is excited about treating patients with new diagnostic and therapeutic modalities available as well as investigating several others in the pipeline to better help patients with these potentially blinding diseases.
He has been the recipient of numerous prestigious awards including the Ronald G. Michels Foundation Fellowship Award, the Heed Ophthalmic Foundation Fellowship Award, Senior Achievement Award from the American Academy of Ophthalmology and Rhett Buckler and Presidential Awards from American Society of Retina Specialists. He is an elected member of Retina Society, Clubs Jules Gonin and serves on the executive committee of the Macula Society.
Dr. Grewal has authored over 190 publications in peer-reviewed medical journals and over 250 presentations at national and international meetings. His research interests span assessment of retinal changes in neurodegenerative diseases, clinical research activities in advanced ocular imaging, surgical techniques and clinical trials for both Retina and Uveitis. Dr Grewal also serves as the Associate Director of the Duke Reading Center, a comprehensive image reading center that specializes in systematic analysis of ophthalmic images in multi-center clinical trials.
Current Appointments & Affiliations
Recent Publications
Corrigendum to Evidence and Consensus-Based Imaging Guidelines in Multifocal Choroiditis With Panuveitis and Punctate Inner Choroiditis-Multimodal Imaging in Uveitis (MUV) Taskforce Report 5. Am J Ophthalmol. 2025;276:272-285.
Journal Article Am J Ophthalmol · November 2025 Full text Link to item CiteFYB-201 Biosimilar ranibizumab (Ongavia/Ranivisio/Cimerli) Efficacy and Safety in Clinical Settings - FORCE study.
Journal Article Eye (Lond) · October 2, 2025 PURPOSE: To understand the early experience of ranibizumab biosimilar (FYB 201) that has been approved in the United Kingdom (Ongavia, Teva Pharmaceuticals, Tel Aviv Israel), United States (Cimerli, Sandoz Inc, Princeton, NJ, USA) and Europe (Ranivisio, Bi ... Full text Link to item CiteEvidence and Consensus-based Imaging Guidelines in Birdshot Chorioretinopathy: Multimodal Imaging in Uveitis (MUV) Taskforce Report 8.
Journal Article Am J Ophthalmol · October 2025 PURPOSE: To develop consensus-based imaging guidelines for diagnosing and monitoring birdshot chorioretinopathy (BSCR). DESIGN: Consensus-based approach guided by literature and an expert committee using a nominal group technique (NGT). METHODS: An expert ... Full text Link to item CiteRecent Grants
A Phase IIb, Randomized, Assessor-Masked, Multicenter Clinical Trial To Assess The Safety And Efficacy Of Subretinal Implantation Of The CPCB-RPE1 Implant In Subjects With Advanced, Dry Age-Related Macular Degeneration (Geographic Atrophy)-PATCH AMD
ResearchPrincipal Investigator · Awarded by Clinical Trials Resource Group, LLC · 2024 - 2031A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults with Active, Non-Infectious Intermediate-, Posterior-, and Panuveitis
Clinical TrialPrincipal Investigator · Awarded by Priovant Therapeutics, Inc · 2024 - 2029A Phase 1/2a study of subretinal administration of OpCT-001 photoreceptor precursor cells derived from iPSCs in patients with primary photoreceptor disease
ResearchPrincipal Investigator · Awarded by BlueRock Therapeutics LP · 2025 - 2029View All Grants